Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 36547666.
- Also identified by DOI 10.1158/1078-0432.CCR-22-2628 and PMC identifier 10272032.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The FDA has an accelerated approval program for drugs that have been identified as promising treatments for serious conditions when the available data suggest that the benefits outweigh the foreseeable risks. All of the currently available treatment options for chronic myeloid leukemia (CML) initially went through the accelerated approval program. Here, a group of academic CML experts, patient panelists, and members from the FDA convened to discuss the utility of the accelerated approval program as it pertains to CML, and the utility of this program in future drug development in this disease. The results of that discussion are summarized here.
Medical subject headings
- Drug Approval
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive